Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)

Inclusion Criteria:

- Diagnosis of RLS using IRLS Study Group (IRLSSG) diagnostic criteria.

- Subjects currently being treated for RLS with a stable dose (for at least 2 weeks) of
ropinirole IR given once daily.

- Subjects with RLS symptoms during both the evening and night or night time only.

- Subjects who have given written informed consent to participate.

Exclusion Criteria:

- Subjects who require treatment of daytime RLS symptoms.

- Signs of secondary RLS, serum ferritin level less than 10 mcg/L.

- Movement Disorders, Clinically significant or unstable medical conditions.

- Abnormal labs, electrocardiogram (ECG) or physical findings.

- Receiving prohibited medications.

- Sleeping habits incompatible with study design.

- Intolerance to ropinirole or other dopamine agonist.

- Pregnant or lactating.

- Women of child-bearing potential who are not practicing an acceptable method of birth
control.